NHS Faces ‘Medicines Shortage Penalty’ as Global Drug Costs Rise and Budget Constraints Bite

The National Health Service faces a paradoxical challenge: its long-standing ability to drive down medicine prices through tough negotiations has made UK supplies less attractive to pharmaceutical manufacturers compared to markets willing to pay premium rates. This dynamic is at the heart of escalating medicine shortages affecting patients across England, according to analysis from the Nuffield Trust.

Mark G Dayan, a health policy expert at the Nuffield Trust, recently highlighted this issue on the BMJ’s Medicine and Science Podcast, explaining how global supply constraints create a stark reality for cash-conscious health systems. “If something’s in short supply, the countries paying more are more likely to get it,” Dayan stated, encapsulating a fundamental challenge facing NHS procurement.

The financial impact of this situation has become substantial and measurable. According to the Royal Pharmaceutical Society, the NHS in England spent £220 million more on medicines in 2022–23 compared to what the same products would have cost in previous years. This figure captures not only higher medicine prices but also the cascading costs of managing shortages across the system.

The UK’s medicines pricing framework, whilst celebrated for delivering some of the lowest medicine costs in the developed world, operates through a reimbursement model that can inadvertently create supply disincentives. The Drug Tariff, updated monthly by NHS England, sets the prices that community pharmacies are reimbursed for dispensing medicines. When pharmaceutical suppliers can obtain higher prices elsewhere—particularly in European markets or the United States—they naturally prioritise those markets for distribution.

This structural tension has intensified in recent years. Reports of medicines shortages have risen significantly since 2021, with recorded incidents peaking in 2024. The supply disruptions span common medications across multiple therapeutic areas, creating daily operational challenges for pharmacists, GPs, and hospital trusts.

The wider impact extends beyond procurement budgets. Community pharmacy leaders and NHS secondary care teams report that frontline clinical staff are increasingly diverting time away from direct patient care to manage medicines shortages. Pharmacy teams must source alternative suppliers, arrange emergency supplies, or liaise with prescribers about therapeutic alternatives. This administrative burden represents a hidden cost to the NHS—one that doesn’t appear in the formal medicines budget but affects service capacity and patient experience.

The reimbursement model itself creates additional complications. Community pharmacies purchase medicines on the open market and are reimbursed by the NHS according to published tariff prices. When a pharmacy’s acquisition cost for a medicine exceeds the tariff reimbursement rate—a situation becoming more common as global prices rise—the pharmacy absorbs the loss. Whilst the system is theoretically designed to balance these variances across a pharmacy’s entire stock, individual medicines can become economically unviable to stock, particularly for smaller independent pharmacies.

The UK Health Departments have begun developing solutions. The Department of Health and Social Care launched a consultation in September 2025 on proposals that would give community pharmacists greater flexibility to supply alternative strengths or formulations of out-of-stock medicines. This change, long advocated by pharmacy organisations, would enable patients to continue treatment whilst supply chains stabilise and could reduce unnecessary GP referrals. However, pharmacy bodies emphasise that this represents a short-term palliative rather than a systematic solution to underlying supply chain vulnerabilities.

Hospital supply chains operate under a different framework. Approximately 70 per cent of medicines used in NHS hospitals in England are supplied via competitive tender arrangements, which provides greater certainty around pricing but requires careful management to prevent supply disruption at tender transitions. Secondary care procurement teams must balance cost control with supply security—a balance that has become increasingly precarious as European medicine prices escalate.

The interconnected nature of global pharmaceutical supply chains means that UK shortages are often driven by events beyond NHS control. Rising manufacturing costs, shipping expenses, and regulatory requirements across European suppliers create upstream price pressures. When UK reimbursement rates remain static whilst these upstream costs increase, medicines become commercially unattractively for suppliers to deliver to British pharmacies.

For 2025–26, NHS England has allocated £3.073 billion to the Community Pharmacy Contractual Framework, including £900 million for medicines margin—a 19.7 per cent increase. However, pharmacy organisations note that this uplift must be carefully managed to avoid undermining efforts to recoup over-delivered margins in previous years, a complex balance that affects reimbursement stability.

The Nuffield Trust’s analysis underscores a strategic dilemma facing UK health policy. Maintaining aggressive price negotiation protects the overall NHS budget and represents responsible use of public resources. Yet the global market dynamics mean that such negotiating strength may inadvertently create supply vulnerabilities compared to health systems in countries with higher pharmaceutical budgets. Finding sustainable solutions requires co-ordinated action across procurement policy, reimbursement frameworks, and international supply chain resilience.

Key Takeaways

• The NHS’s success in negotiating low medicine prices may inadvertently reduce the attractiveness of UK markets to pharmaceutical suppliers compared to higher-paying countries, contributing to medicine shortages
• The NHS in England spent £220 million additional on medicines in 2022–23 as a direct result of managing supply disruptions and sourcing alternatives
• Proposed government reforms would allow community pharmacists greater flexibility to supply alternative medicine strengths during shortages, potentially improving patient access whilst supply issues are resolved
• Frontline clinical staff across community and hospital services are spending increasing time managing supply disruptions rather than direct patient care

What This Means for Kent Residents

Kent residents relying on NHS services may encounter temporary medicine supply challenges, though local NHS trusts and community pharmacies are actively managing these issues. If you experience difficulty obtaining a prescribed medicine, speak to your community pharmacist, who can advise on alternatives or arrange urgent supplies. The NHS Kent and Medway Integrated Care Board, together with local hospital trusts including Maidstone and Tunbridge Wells NHS Trust and East Kent Hospitals University NHS Foundation Trust, are working with primary care networks to ensure critical medicines remain accessible. For ongoing concerns about medicine availability, contact your GP practice or local pharmacy, which can escalate issues to NHS England if necessary.